EMEA-003215-PIP01-22-M01 - paediatric investigation plan

vamikibart

Key facts

• Active Substance:
  vamikibart
• Therapeutic area:
  Eye disorders
• Decision number:
  P/0091/2024
• PIP number:
  EMEA-003215-PIP01-22-M01
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of uveitic macular oedema
• Route(s) of administration:
  Intravitreal use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  12/04/2024

Decision

P/0072/2023 : EMA decision of 12 april 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vamikibart (EMEA- 003215-PIP01-22-M01)

AdoptedReference Number: EMA/137672/2024